about
Independent course of childhood auditory hallucinations: a sequential 3-year follow-up study.The pilot project 'Soteria Berne'. Clinical experiences and resultsGenetic studies of bipolar affective disorder in large familiesEarly intervention and recovery for young people with early psychosis: consensus statementPathways to care for first-episode psychosis in an early detection healthcare sector: part of the Scandinavian TIPS studyA three-component-system hypothesis of psychosis. Impairment of binocular depth inversion as an indicator of a functional dysequilibriumUnderstanding the structure of the psychopathy checklist - revised: an exploration of methodological confusionMental health problems in the workplace: changes in employers' knowledge, attitudes and practices in England 2006-2010.Evaluative delusions: their significance for philosophy and psychiatry.The role of human rights and personal dignity in the rehabilitation of chronic psychiatric patients. A rural therapeutic community in Yanbian, Jilin.Rehabilitative effect of music therapy for residual schizophrenia. A one-month randomised controlled trial in Shanghai.Making music out of noise--the cost function approach to evaluation.Identification with the therapist's functions and ego-building in the treatment of schizophrenia.Magnetic resonance imaging and its applications in neuropsychiatry.Psychiatry and the new magnetic resonance era.Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data.Collecting service use data for economic evaluation in DSPD populations: development of the Secure Facilities Service Use Schedule.Cognitive decline following psychosis onset: data from the PACE clinic.Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder.Antipsychotics and diabetes: review of non-prospective data.A glutamatergic deficiency model of schizophrenia.Cholinergic aspects of schizophrenia.Glutamatergic aspects of schizophrenia.Cognitive deficit in schizophrenia and its neurochemical basis.An approach to treatment resistance in schizophrenia.CNS drug discovery in the 21st century. From genomics to combinatorial chemistry and back.Olanzapine in the long-term treatment of schizophrenia.Review of recent clinical studies with olanzapine.Olanzapine: a basic science update.Olanzapine: preclinical pharmacology and recent findings.Understanding the roles of genome and envirome: methods in genetic epidemiology.Genetics of novel therapeutic targets in schizophrenia.Behavioural pharmacology of the new generation of antipsychotic agents.Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors.In vivo neuropharmacology of schizophrenia.Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics.Cognitive effects of conventional and atypical antipsychotics in schizophrenia.Psychopharmacology of olanzapine. A review.The social costs of anxiety disorders.Brain morphology in antipsychotic-naïve schizophrenia: a study of multiple brain structures.
P1433
Q22115488-7b78552a-4265-d0a1-2d23-220edab1e830Q28183372-233FC647-7AB5-4B56-B1A0-5F18D6F6FFFAQ28206008-8D6B006B-D7BF-49F8-A442-82CB00772F8BQ28264755-6AB3774D-B658-473B-8822-82860A27FB27Q28264763-1849B726-1807-4E98-8EE1-43A8AE33C6F5Q28273592-72F789B4-5646-46FD-841C-2C3C550A2F4DQ28300100-32DC7550-4DB9-452D-920F-8AFCDD258F79Q30223146-AD6549B4-2CE2-45B6-98FC-846A8CBF0CA2Q30368821-CD0AA54F-B528-4642-98D2-D75491D3CC5AQ30419994-07D0BFDD-1FFF-4390-9594-56B00426611FQ30419999-03A2C50F-5AF6-498F-A0EE-9CF652E5DDA4Q30432052-DBB646A5-44CC-4EF5-BEDF-4BF5B7E09201Q30466021-F4B3D06E-D72A-4BFC-9826-E89390061872Q30558952-FB691FC6-9990-4F37-B939-DF95F6923D4CQ30558957-EABE24C5-93AE-41EE-9711-32F9A20E30BAQ30918134-31C54D94-06C6-4496-A06F-2A19C72C2D84Q31110996-A8A84825-05A6-4326-9D6E-C3C0CA8E3120Q31138788-0B0B4EAE-1C78-49AA-B4BB-1A82C5C9BF9DQ31966529-E5B3C5FF-09C5-4183-8EDA-ED0B1603E718Q33200672-5053DAA7-97B5-4418-82C3-9E0AFEDAA98BQ33598404-0589EEF4-4B81-4FB1-A18B-7898FA32DDE8Q33598409-D0D3B9D9-9C90-43DB-A38F-26D1381754FFQ33598415-E437AA05-BDF7-45D9-9922-1731BC033643Q33598420-527F88B9-EB45-4D8B-AD2A-356081B8F360Q33598426-7CE91311-3F3F-4925-BF4B-77CD7C922389Q33598431-83081229-0BB6-4D93-8B6F-DB4B0976C55EQ33598436-E1FC38EC-814D-4E3A-BAFC-CCCE93CD3A33Q33598440-A626CFEF-3F87-473A-8DF7-FF746ABCB3DDQ33598446-4F60EDF0-5A1A-4DC2-9D39-8A4D3C027885Q33598450-95D720DF-174E-4EF3-A0EA-3D75555DCF90Q33943552-FC8B3C6E-44FF-4BF1-8B0E-9894AB9EBD55Q33960607-393D0AFE-102C-4FAD-9F35-71A45321F35CQ33960613-82E4A95A-6AFB-45AB-B874-87F7ABFAB8D5Q33960618-479FC524-1184-48BB-A533-941E1B397058Q33960625-C9CA6C95-8464-4E32-96A4-78344D0F7112Q33960632-0F2E7A4B-66E3-4C8B-B71E-29B8E5A5A63CQ33960636-831B6942-FAA1-4938-9AF3-868772D895D1Q33960644-B4C71FEB-CDF0-4074-A6D2-8FF7FED99F8EQ34059079-CF5F8823-6E8F-475B-B73C-1DD2F5B74405Q34151056-6CDF3781-AA60-4600-9A4F-A4FB19EDDDA7
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift
@nl
wissenschaftliche Fachzeitschrift
@de
name
The British journal of psychiatry. Supplement
@ast
The British journal of psychiatry. Supplement
@en
The British journal of psychiatry. Supplement
@es
The British journal of psychiatry. Supplement
@it
The British journal of psychiatry. Supplement
@nl
type
label
The British journal of psychiatry. Supplement
@ast
The British journal of psychiatry. Supplement
@en
The British journal of psychiatry. Supplement
@es
The British journal of psychiatry. Supplement
@it
The British journal of psychiatry. Supplement
@nl
altLabel
Br J Psychiatry Suppl
@en
The British Journal of Psychiatry
@en
prefLabel
The British journal of psychiatry. Supplement
@ast
The British journal of psychiatry. Supplement
@en
The British journal of psychiatry. Supplement
@es
The British journal of psychiatry. Supplement
@it
The British journal of psychiatry. Supplement
@nl
P1055
P1156
P1476
The British journal of psychiatry. Supplement
@en